Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.

BACKGROUND:Galectin-3 (Gal-3) is an emerging biomarker in heart failure that is involved in fibrosis and inflammation. However, its potential value as a prognostic marker in atrial fibrillation (AF) is unknown. The aim of this study was to assess the impact of AF catheter ablation on Gal-3 and evalu...

Full description

Bibliographic Details
Main Authors: Jelena Kornej, Josephin Schmidl, Laura Ueberham, Silke John, Sait Daneschnejad, Borislav Dinov, Gerhard Hindricks, Volker Adams, Daniela Husser, Andreas Bollmann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4398460?pdf=render
id doaj-9a7665eadfc040ac9a9bbec52b56a845
record_format Article
spelling doaj-9a7665eadfc040ac9a9bbec52b56a8452020-11-24T21:50:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012357410.1371/journal.pone.0123574Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.Jelena KornejJosephin SchmidlLaura UeberhamSilke JohnSait DaneschnejadBorislav DinovGerhard HindricksVolker AdamsDaniela HusserAndreas BollmannBACKGROUND:Galectin-3 (Gal-3) is an emerging biomarker in heart failure that is involved in fibrosis and inflammation. However, its potential value as a prognostic marker in atrial fibrillation (AF) is unknown. The aim of this study was to assess the impact of AF catheter ablation on Gal-3 and evaluate its prognostic impact for predicting rhythm outcome after catheter ablation. METHODS:Gal-3 was measured at baseline and after 6 months using specific ELISA. AF recurrences were defined as any atrial arrhythmia lasting longer than 30 sec within 6 months after ablation. RESULTS:In 105 AF patients (65% males, age 62±9 years, 52% paroxysmal AF) undergoing catheter ablation, Gal-3 was measured at baseline and after 6 months and compared with an AF-free control cohort (n=14, 50 % males, age 58±11 years). Gal-3 was higher in AF patients compared with AF-free controls (7.8±2.9 vs. 5.8±1.8, ng/mL, p=0.013). However, on multivariable analysis, BMI (p=0.007) but not AF (p=0.068) was associated with Gal-3. In the AF cohort, on univariable analysis higher Gal-3 levels were associated with female gender (p=0.028), higher BMI (p=0.005) and both CHADS2 (p=0.008) and CHA2DS2-VASC (p=0.016) scores, however, on multivariable analysis only BMI remained significantly associated with baseline Gal-3 (p=0.016). Gal-3 was similar 6 months after AF catheter ablation and was not associated with sinus rhythm maintenance. CONCLUSIONS:Although galectin-3 levels are higher in AF patients, this is driven by cardiometabolic co-morbidities and not heart rhythm. Gal-3 is not useful for predicting rhythm outcome of catheter ablation.http://europepmc.org/articles/PMC4398460?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jelena Kornej
Josephin Schmidl
Laura Ueberham
Silke John
Sait Daneschnejad
Borislav Dinov
Gerhard Hindricks
Volker Adams
Daniela Husser
Andreas Bollmann
spellingShingle Jelena Kornej
Josephin Schmidl
Laura Ueberham
Silke John
Sait Daneschnejad
Borislav Dinov
Gerhard Hindricks
Volker Adams
Daniela Husser
Andreas Bollmann
Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
PLoS ONE
author_facet Jelena Kornej
Josephin Schmidl
Laura Ueberham
Silke John
Sait Daneschnejad
Borislav Dinov
Gerhard Hindricks
Volker Adams
Daniela Husser
Andreas Bollmann
author_sort Jelena Kornej
title Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
title_short Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
title_full Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
title_fullStr Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
title_full_unstemmed Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
title_sort galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description BACKGROUND:Galectin-3 (Gal-3) is an emerging biomarker in heart failure that is involved in fibrosis and inflammation. However, its potential value as a prognostic marker in atrial fibrillation (AF) is unknown. The aim of this study was to assess the impact of AF catheter ablation on Gal-3 and evaluate its prognostic impact for predicting rhythm outcome after catheter ablation. METHODS:Gal-3 was measured at baseline and after 6 months using specific ELISA. AF recurrences were defined as any atrial arrhythmia lasting longer than 30 sec within 6 months after ablation. RESULTS:In 105 AF patients (65% males, age 62±9 years, 52% paroxysmal AF) undergoing catheter ablation, Gal-3 was measured at baseline and after 6 months and compared with an AF-free control cohort (n=14, 50 % males, age 58±11 years). Gal-3 was higher in AF patients compared with AF-free controls (7.8±2.9 vs. 5.8±1.8, ng/mL, p=0.013). However, on multivariable analysis, BMI (p=0.007) but not AF (p=0.068) was associated with Gal-3. In the AF cohort, on univariable analysis higher Gal-3 levels were associated with female gender (p=0.028), higher BMI (p=0.005) and both CHADS2 (p=0.008) and CHA2DS2-VASC (p=0.016) scores, however, on multivariable analysis only BMI remained significantly associated with baseline Gal-3 (p=0.016). Gal-3 was similar 6 months after AF catheter ablation and was not associated with sinus rhythm maintenance. CONCLUSIONS:Although galectin-3 levels are higher in AF patients, this is driven by cardiometabolic co-morbidities and not heart rhythm. Gal-3 is not useful for predicting rhythm outcome of catheter ablation.
url http://europepmc.org/articles/PMC4398460?pdf=render
work_keys_str_mv AT jelenakornej galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT josephinschmidl galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT lauraueberham galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT silkejohn galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT saitdaneschnejad galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT borislavdinov galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT gerhardhindricks galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT volkeradams galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT danielahusser galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
AT andreasbollmann galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation
_version_ 1725883092137148416